Rare Disease Day is coming soon—a time to shine a light on the millions of people living with rare diseases, like scleroderma. At the Scleroderma Research Foundation (SRF), we believe that raising awareness is a critical first step. That’s why we’re also taking action—driving progress in rare disease research through our clinical trial, CONQUEST.
Launched by the SRF in April 2024, CONQUEST was developed with input from partner biopharmaceutical companies to accelerate the development of treatment options for scleroderma. For our initial cohort of patients, the SRF is enrolling patient with scleroderma-associated interstitial lung disease (SSc-ILD).
With 90 clinical trial sites open across 20 countries, and more coming soon, eligible individuals with SSc-ILD now have the opportunity to enroll at locations worldwide. By leveraging a global network of scleroderma treatment centers, CONQUEST is set to drive meaningful progress in scleroderma research, aiming to enroll 430 patients in its initial phase.
Want to know if you qualify to get involved with CONQUEST? Take the new pre-screener survey. To access the pre-screener, visit the CONQUEST page on the SRF website, and click “Learn More about enrolling in CONQUEST.” From there, click “See if I May Qualify” to take the pre-screener and evaluate CONQUEST as an option for you.
And stay up to date—new trial sites are being added regularly. Check out the interactive map on our website to see where sites are now and coming soon.
